Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities:
Net income	$ 26,251,000	$ 11,285,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	10,586,000	10,048,000
Equity in earnings of unconsolidated investments	(67,000)	(1,535,000)
Unrealized gains on marketable equity securities	(14,399,000)	(1,386,000)
(Gains)/losses on sale of marketable securities	(344,000)	492,000
Gain on sale of unconsolidated company	(1,024,000)	0
Deferred income taxes	(2,484,000)	(331,000)
Stock–based compensation	793,000	639,000
Changes in operating assets and liabilities:
Accounts receivable	(17,119,000)	(3,148,000)
Inventories	623,000	142,000
Prepaid expenses and other assets	3,153,000	1,957,000
Operating lease obligations	55,000	(316,000)
Trade accounts payable	1,503,000	(4,018,000)
Accrued payroll	(19,954,000)	(15,800,000)
Amounts due to third party payors	1,619,000	48,000
Accrued risk reserves	4,978,000	3,157,000
Contract liabilities	7,667,000	0
Other current liabilities	1,311,000	5,407,000
Other noncurrent liabilities	1,530,000	6,554,000
Net cash provided by operating activities	9,646,000	13,857,000
Cash Flows From Investing Activities:
Purchases of property and equipment	(5,955,000)	(6,640,000)
Proceeds from sale of unconsolidated company	2,100,000	0
Investments in unconsolidated companies	(1,488,000)	0
Collections of notes receivable	16,000	2,000
Purchases of marketable securities	(8,703,000)	(10,281,000)
Proceeds from sale of marketable securities	11,615,000	15,492,000
Net cash used in investing activities	(2,415,000)	(1,427,000)
Cash Flows From Financing Activities:
Principal payments under finance lease obligations	(860,000)	(1,218,000)
Dividends paid to common stockholders	(9,051,000)	(8,748,000)
Issuance of common stock	8,412,000	0
Repurchase of common shares	(9,900,000)	(2,482,000)
Entrance fee refunds	(668,000)	(171,000)
Net cash used in financing activities	(12,067,000)	(12,619,000)
Net Decrease in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	(4,836,000)	(189,000)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning of Period	125,968,000	74,865,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, End of Period	121,132,000	74,676,000
Balance Sheet Classifications:
Cash and cash equivalents	93,982,000	46,144,000
Restricted Cash and Cash Equivalents	27,150,000	28,532,000
Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$ 121,132,000	$ 74,676,000